Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials testing an experimental treatment in which patients' own immune cells are genetically engineered to fight their cancer. [More]
CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Cancer Research Technology, the commercialization and development arm of Cancer Research UK and BioInvent International today announce the start of a two-year research collaboration with leading antibody researchers at the University of Southampton. [More]
Iron oxide nanoparticles selectively target cell surface markers in tumor microenvironments

Iron oxide nanoparticles selectively target cell surface markers in tumor microenvironments

Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells. [More]
Women face Lymphangioleiomyomatosis risk during their childbearing years

Women face Lymphangioleiomyomatosis risk during their childbearing years

A rare and potentially deadly lung disease called Lymphangioleiomyomatosis (LAM) strikes women during their childbearing years. [More]
Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return. [More]
Immunotherapy reverses memory problems in animal model of Alzheimer's disease

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience. [More]
Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety. [More]
IMDC prognostic model valid in second-line RCC therapy

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
Genetic flaws in bowel cancer may trigger immune response at site of tumours

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today (Monday) in the journal Oncoimmunology. [More]
Study reveals functional heterogeneity of CD4 T cells in immune systems

Study reveals functional heterogeneity of CD4 T cells in immune systems

Utilizing a novel transgenic mouse model, Edward Usherwood, PhD of Dartmouth's Norris Cotton Cancer Center and collaborators found that CD4 T cells divide into two different populations that each has a different job. One type performs antiviral functions, and the other survives life in the host. [More]
New triple combination therapy shows promise in controlling advanced melanoma

New triple combination therapy shows promise in controlling advanced melanoma

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects. [More]
Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes. [More]
New range of purified, soluble immunoreceptors announced by AMSBIO

New range of purified, soluble immunoreceptors announced by AMSBIO

AMSBIO has announced a new range of purified, soluble immunoreceptors involved in key signalling pathways. Together with new indoleamine 2,3-dioxygenase (IDO) assay kits these products that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies that serve as positive controls for inhibition. [More]
ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). [More]
TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office. [More]
Study reveals novel approach to treat breast cancer

Study reveals novel approach to treat breast cancer

A means of reprogramming a flawed immune response into an efficient anti-tumoral one was brought to light by the results of a translational trial relating to breast cancer. Thanks to the innovative combination of mathematical modelisation and experimentation, only 20 tests were necessary, whereas traditional experimentation would have required 596 tests to obtain the same results. [More]
Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers. [More]
Advertisement
Advertisement